Lung Cancer Breakthrough: Blocking Growth Hormone Could Unlock New Treatments
Researchers at Ohio University have identified a potential new strategy in the fight against lung cancer, particularly the most common form, Non-Small Cell Lung Cancer (NSCLC). The study, led by Dr. John J. Kopchick, suggests that blocking the growth hormone receptor (GHR) may enhance the effectiveness of existing treatments and improve survival rates.
The Link Between Growth Hormone and Lung Cancer
Lung cancer remains a leading cause of cancer-related deaths globally. While treatments like surgery, chemotherapy, and radiation have advanced, many patients develop resistance, hindering successful outcomes. Dr. Kopchick’s team discovered significantly higher levels of the GHR in lung tumor samples compared to healthy lung tissue. This finding is crucial, as previous research hinted at a role for growth hormone in fueling cancer cell growth and resistance to therapy.
The research revealed a stark correlation: patients with tumors exhibiting high GHR levels had significantly shorter survival times – averaging 36-40 months – compared to those with low GHR levels, who lived approximately 66 months. This suggests the GHR isn’t just present in tumors, but actively contributes to their aggressive behavior.
How Blocking the Receptor Could Improve Treatment
Laboratory experiments demonstrated that growth hormone (GH) increases the resistance of lung cancer cells to common chemotherapy drugs like doxorubicin and cisplatin. GH achieves this by boosting the activity of drug-efflux pumps, essentially allowing cancer cells to pump the drugs out before they can accept effect. It also promotes changes associated with tumor spread and inhibits cell death.
Fortunately, a potential solution already exists. The team tested pegvisomant, a drug developed by Dr. Kopchick in 1987 and currently FDA-approved for treating acromegaly (a condition caused by excess GH). Pegvisomant effectively blocks the GHR, reversing the harmful effects of GH and making cancer cells more susceptible to chemotherapy. In fact, the research indicated that combining pegvisomant with chemotherapy could even allow for lower doses of chemotherapy to be used, potentially reducing side effects.
Beyond Lung Cancer: A Broader Impact?
While this research focuses on NSCLC, the implications could extend to other cancers. Studies have already shown promising results in mouse models, with combinations of therapy and pegvisomant positively treating melanoma, pancreatic, and liver cancers. This suggests that targeting the GHR could be a broadly applicable strategy in oncology.
Future Directions and Clinical Trials
The next step involves testing the effectiveness of this approach in mouse models of lung cancer. Successful results will pave the way for clinical trials to determine the safety and efficacy of GHR antagonism in human patients. The research was conducted by a collaborative team at Ohio University’s Institute for Molecular Medicine and the Aging, the Diabetes Institute, and other departments.
Did you know?
Dr. John J. Kopchick is an internationally recognized leader in the field of growth hormone research, with a career spanning over three decades.
FAQ
Q: What is the growth hormone receptor?
A: The growth hormone receptor (GHR) is a protein in cells that binds to growth hormone, regulating growth, metabolism, and development. Research suggests it also plays a role in cancer progression.
Q: What is pegvisomant?
A: Pegvisomant is a drug that blocks the growth hormone receptor. It’s currently approved to treat acromegaly and is being investigated as a potential cancer therapy.
Q: Is this a cure for lung cancer?
A: No, this research is still in its early stages. While promising, further studies and clinical trials are needed to determine if blocking the growth hormone receptor is a safe and effective treatment for lung cancer.
Q: What is Non-Small Cell Lung Cancer (NSCLC)?
A: NSCLC is the most common type of lung cancer, accounting for 80-85% of all cases.
Q: Where was this research conducted?
A: This research was conducted at Ohio University’s Institute for Molecular Medicine and the Aging, the Diabetes Institute, the Translational Biomedical Sciences Program, and the Departments of Biomedical Sciences and Biological Sciences.
Pro Tip: Early detection is crucial for successful lung cancer treatment. Talk to your doctor about screening options if you are at high risk.
Stay informed about the latest advancements in cancer research. Learn more about the Heritage College of Osteopathic Medicine at Ohio University.
